MA58173B1 - Composition liquide comprenant de l'ibuprofène et de la phényléphrine - Google Patents

Composition liquide comprenant de l'ibuprofène et de la phényléphrine

Info

Publication number
MA58173B1
MA58173B1 MA58173A MA58173A MA58173B1 MA 58173 B1 MA58173 B1 MA 58173B1 MA 58173 A MA58173 A MA 58173A MA 58173 A MA58173 A MA 58173A MA 58173 B1 MA58173 B1 MA 58173B1
Authority
MA
Morocco
Prior art keywords
phenylephrine
ibuprofen
composition
relates
present
Prior art date
Application number
MA58173A
Other languages
English (en)
Inventor
García José Ángel Sánchez
De La Torre Marta Vicario
Menéndez Nuria Sanz
Sánchez José Carlos Iglesias
Serna Luis Sante
Original Assignee
Nutra Essential Otc S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutra Essential Otc S L filed Critical Nutra Essential Otc S L
Publication of MA58173B1 publication Critical patent/MA58173B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique liquide destinée à une administration orale sous la forme d'une suspension qui comprend la combinaison d'ibuprofène et de phényléphrine, ou d'un sel pharmaceutiquement acceptable correspondant, en tant que principes actifs, et d'hypromellose, de gomme xanthane, de maltitol liquide, de glycérine et d'eau. La composition est stable, présente de bonnes propriétés organoleptiques et présente un excellent profil pharmacocinétique, ce qui permet une absorption rapide des médicaments. La présente invention concerne également l'utilisation de la composition pour traiter les symptômes de la grippe et du rhume banal, en particulier chez l'adulte et l'enfant de plus de 7 ans.
MA58173A 2019-12-23 2020-12-18 Composition liquide comprenant de l'ibuprofène et de la phényléphrine MA58173B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19383192 2019-12-23
PCT/EP2020/087107 WO2021130126A1 (fr) 2019-12-23 2020-12-18 Composition liquide comprenant de l'ibuprofène et de la phényléphrine

Publications (1)

Publication Number Publication Date
MA58173B1 true MA58173B1 (fr) 2024-03-29

Family

ID=69172579

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58173A MA58173B1 (fr) 2019-12-23 2020-12-18 Composition liquide comprenant de l'ibuprofène et de la phényléphrine

Country Status (20)

Country Link
US (1) US12508240B2 (fr)
EP (1) EP4081187B1 (fr)
JP (1) JP7614207B2 (fr)
CN (1) CN114828829B8 (fr)
AU (1) AU2020410965B2 (fr)
BR (1) BR112022012308A2 (fr)
CA (1) CA3164495C (fr)
DK (1) DK4081187T3 (fr)
ES (1) ES2969035T3 (fr)
FI (1) FI4081187T3 (fr)
HR (1) HRP20240108T1 (fr)
HU (1) HUE065040T2 (fr)
MA (1) MA58173B1 (fr)
MD (1) MD4081187T2 (fr)
MX (1) MX2022007504A (fr)
PL (1) PL4081187T3 (fr)
PT (1) PT4081187T (fr)
RS (1) RS65089B1 (fr)
SI (1) SI4081187T1 (fr)
WO (1) WO2021130126A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3245742A1 (fr) * 2022-03-15 2023-09-21 Habit Factory In Sweden Ab Composition de nicotine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB971700A (en) 1961-02-02 1964-09-30 Boots Pure Drug Co Ltd Anti-Inflammatory Agents
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
US4975465A (en) * 1989-03-28 1990-12-04 American Home Products Corporation Orally administrable ibuprofen compositions
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
US5759579A (en) 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
WO2006022996A2 (fr) 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Forme posologique contenant des medicaments multiples
US8940796B2 (en) 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20070254027A1 (en) * 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20080014275A1 (en) 2006-07-13 2008-01-17 Buehler Gail K Pharmaceutical suspensions and related methods
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
WO2008064192A2 (fr) * 2006-11-21 2008-05-29 Mcneil-Ppc, Inc. Suspensions analgésiques à libération modifiée
WO2009012590A1 (fr) 2007-07-23 2009-01-29 Kingsway Pharmaceuticals Inc. Formulations thérapeutiques pour le traitement de symptômes apparentés au rhume et à la grippe
WO2009083759A1 (fr) * 2008-01-03 2009-07-09 Wockhardt Research Centre Suspension pharmaceutique orale contenant du paracétamol et de l'ibuprofène
WO2009100331A2 (fr) 2008-02-06 2009-08-13 The Procter & Gamble Company Compositions, méthodes et kits de stimulation de la réponse immunitaire à une maladie respiratoire
JP5426195B2 (ja) * 2008-03-10 2014-02-26 第一三共ヘルスケア株式会社 イブプロフェン含有安定化内服液
EP2961377B1 (fr) * 2013-02-28 2020-03-18 PF Consumer Healthcare 1 LLC Stabilité ameliorée de nouvelles compositions liquides
EP3110396B1 (fr) 2014-02-27 2018-07-04 The Procter and Gamble Company Médicament à perception de goût amer réduite

Also Published As

Publication number Publication date
MD4081187T2 (ro) 2024-05-31
JP2023508085A (ja) 2023-02-28
JP7614207B2 (ja) 2025-01-15
HUE065040T2 (hu) 2024-04-28
SI4081187T1 (sl) 2024-03-29
EP4081187A1 (fr) 2022-11-02
CA3164495C (fr) 2024-11-05
WO2021130126A1 (fr) 2021-07-01
US12508240B2 (en) 2025-12-30
AU2020410965A1 (en) 2022-06-30
MX2022007504A (es) 2022-07-01
DK4081187T3 (da) 2024-01-02
CA3164495A1 (fr) 2021-07-01
PT4081187T (pt) 2024-02-14
FI4081187T3 (fi) 2024-01-31
US20230012144A1 (en) 2023-01-12
CN114828829B (zh) 2025-07-11
EP4081187B1 (fr) 2023-12-13
BR112022012308A2 (pt) 2022-09-06
ES2969035T3 (es) 2024-05-16
PL4081187T3 (pl) 2024-04-08
AU2020410965B2 (en) 2025-12-11
RS65089B1 (sr) 2024-02-29
CN114828829B8 (zh) 2025-08-15
HRP20240108T1 (hr) 2024-04-12
CN114828829A (zh) 2022-07-29

Similar Documents

Publication Publication Date Title
CN105007891B (zh) 新液体组合物的增强的稳定性
ES3057264T3 (en) 5-amino-2,3-dihydro-1,4-phthalazinedione for use in the treatment of coronaviral infections
JP2018523635A5 (fr)
MA44206B1 (fr) Comprimé orodispersible comprenant estetrol
JP7458159B2 (ja) 眼科組成物
WO2021170290A1 (fr) Inhibiteurs de désubiquitinases humaines pour le traitement d'infections coronavirales
Aoki Antiviral drugs for influenza and other respiratory virus infections
JP2003128549A (ja) 粘膜適用組成物
ES2337501T3 (es) Preparacion oftalmica que comprende goma de xantano y terpenoide.
JP2003128583A (ja) 清涼化組成物
ES2318277T3 (es) Composicion farmaceutica que compresnde acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico.
FR3102058A1 (fr) Utilisation de NMN pour la prévention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
CN114828829B8 (zh) 包含布洛芬和去氧肾上腺素的液体组合物
JP6666661B2 (ja) 局所粘膜適用水性組成物
AR083393A1 (es) Composicion farmaceutica liquida para el tratamiento y prevencion del dolor
JP2011111418A (ja) 口腔内局所投与に適したウイルス感染予防製剤
JP2003055223A (ja) 安定化された組成物
CN105283186A (zh) 氯苯那敏或其盐的稳定化方法
JP2003055222A (ja) 安定化された組成物
MA62096B1 (fr) Composition ophtalmique contenant de la lévofloxacine et du kétorolac, son procédé de préparation et son utilisation
JP2003055224A (ja) 安定化された組成物
JP2021155414A (ja) ソフトコンタクトレンズ用眼科組成物
JP4358535B2 (ja) アセトアミノフェンを含有する安定な水性医薬組成物
JP6616968B2 (ja) 医薬組成物
JP2007277233A (ja) 眼科用組成物